Sinew Pharma Inc.

SINEW PHARMA INC. (stock code: 6634.TWO) is a publicly-listed biotech company dedicated on the development of therapeutic products for solving urgent and important unmet medical needs. SINEW aspires to become a leading pharmaceutical company by actively engaging in R&D for drug development of metabolic dysfunction-associated steatohepatitis, MASH (formerly known as non-alcoholic steatohepatitis, NASH) as well as for the world's first non-hepatotoxic acetaminophen. Current pipeline includes six products, two of which are dedicated to MASH treatment, three aim to address liver toxicity issues arising from the widely used painkiller acetaminophen and its combinations (e.g., with a non-addictive kappa-opioid for postoperative pain management), and one serves as an antidote for acetaminophen poisoning.